KLRK1 and plasma cell myeloma: Additionally, NKG2D-CAR-induced NK cells incorporating a costimulatory domain exhibited significant and robust anti-tumor activity, leading to enhanced tumor clearance and prolonged survival in preclinical models of tumors expressing NKG2D ligands, including ovarian cancer, glioblastoma, and multiple myeloma (50).